FLT4 and neoplasm: SAR131675, a highly selective receptor tyrosine kinase inhibitor of VEGFR3, displays significant antitumour and antimetastatic activities in vivo through inhibition of lymphangiogenesis and tumour-associated macrophage invasion in biliary tract cancer [22].